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Key points
●● Asthma in the elderly can be difficult to identify due to modifications of its clinical features and 
functional characteristics.
●● Several comorbidities are associated with asthma in the elderly, and this association differs from 
that observed in younger patients.
●● In clinical practice, physicians should treat comorbidities that are correlated with asthma 
(i.e. rhinitis or gastro-oesophageal reflux), assess comorbidities that may influence asthma 
outcomes (i.e. depression or cognitive impairment) and try to prevent comorbidities related to  
drug-associated side-effects (i.e. cataracts, arrhythmias or osteoporosis).
●● “Geriatric asthma” should be the preferred term because it implies the comprehensive and 
multidimensional approach to the disease in the older populations, whereas “asthma in the elderly” 
is only descriptive of the occurrence of the disease in this age range.
Educational aims
●● To present critical issues in performing differential diagnosis of asthma in the elderly.
●● To offer the instrument to implement the management of asthma in the most advanced ages.
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Asthma is a chronic airway disease that affects all ages, but does this definition also include the 
elderly? Traditionally, asthma has been considered a disease of younger age, but epidemiological 
studies and clinical experience support the concept that asthma is as prevalent in older age as it 
is in the young. With the ever-increasing elderly population worldwide, the detection and proper 
management of the disease in old age may have a great impact from the public health perspective. 
Whether asthma in the elderly maintains the same characteristics as in young populations is an 
interesting matter. The diagnostic process in older individuals with suspected asthma follows the 
same steps, namely a detailed history supported by clinical examination and laboratory investi-
gations; however, it should be recognised that elderly patients may partially lose reversibility of 
airway obstruction. The correct interpretation of spirometric curves in the elderly should take into 
account the physiological changes in the respiratory system. Several factors contribute to delay-
ing the diagnosis of asthma in the elderly, including the age-related impairment in perception of 
breathlessness. The management of asthma in advanced age is complicated by the comorbidities 
and polypharmacotherapy, which advocate for a comprehensive approach with a multidimen-
sional assessment. It should be emphasised that older age frequently represents an exclusion 
criterion for eligibility in clinical trials, and current asthma medications have rarely been tested 
in elderly asthmatics. Ageing is associated with pharmacokinetic changes of the medications. 
As a consequence, absorption, distribution, metabolism and excretion of antiasthmatic medica-
tions can be variably affected. Similarly, drug-to-drug interactions may reduce the effectiveness 
of inhaled medications and increase the risk of side-effects. For this reason, we propose the term 
“geriatric asthma” be preferred to the more generic “asthma in the elderly”.
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Introduction
Asthma in the elderly is largely under- or 
misdiagnosed and, thus, undertreated. This is 
mainly due to the erroneous belief that asthma 
is a disease of childhood. It is not rare to fall into 
the trap of attributing respiratory symptoms 
suggestive of asthma to conditions other than 
asthma, i.e. chronic obstructive pulmonary 
disease (COPD), when they occur at older ages. 
Old observational reports and new epidemiological 
studies confirm that asthma is as frequent in older 
as it is in younger populations. Lee and Stretton 
[1] in 1972 and later Burr et al. [2] in 1979 showed 
that features of asthma could be documented 
in individuals aged 70 years and over, to the 
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same proportion of asthma as in younger ages. 
A MEDLINE search using “asthma” and “elderly” 
as MeSH (Medical Subject Headings) terms has 
yielded a steadily increase in articles with time, 
implying a better understanding of the disease 
and greater attention to the topic. The prevalence 
of asthma in the elderly is difficult to establish, 
and this is due on one hand to the heterogeneity 
of the clinical and functional presentations of the 
disease in the aged population (including the poor 
perception of symptoms and the tendency to lose 
the airway reversibility), and on the other hand, 
to the definition of “elderly”, which is usually, but 
not always, considered to begin at 65 years of age. 
In addition, little information is available on the 
rate of relapse after asthma remission in later life. 
 Several  studies in European and US populations 
have shown that asthma prevalence among 
people aged over 65 years ranges from 1.8% to 
10.9% [3]. If anything, the burden of asthma in the 
elderly is more relevant than in young asthmatics, 
regarding costs, quality of life, hospitalisation and 
mortality [4, 5].
The recognition of age of onset is one of the 
mandatory steps when dealing with older asth-
matics, because it allows us to distinguish 
between two entities that may even behave as 
different diseases, referred as “early” and “late” 
onset asthma. The late-onset disease appears to 
be more severe and less atopic. Is it possible that 
asthma occurring for the first time in the most 
advanced ages is a different disease than asthma 
that begins early in life and carries over to older 
ages? Asthma that starts in childhood may persist 
until the most advanced ages, or may disappear 
in adult ages and relapse at older ages. In these 
cases, the disease can be definitely regarded as 
early-onset asthma. The latter also includes a 
condition in which the clinical manifestations of 
asthma occur in older age but recall bias does 
not allow establishment of the age of onset. The 
opposite scenario includes asthma that makes 
its appearance for the first time at older ages 
(late-onset asthma). The question is at which age 
to set the threshold for the definition of “late” 
onset. We propose that 65 years of age should 
be the cut-off to identify a late-onset disease, as 
opposed to, for example, 45 years.
It must be stated that the knowledge of asthma 
in the elderly suffers from the fact that there has 
been very little original research in this field. This 
is because advanced age is invariably an exclusion 
criterion in almost all randomised clinical trials 
(RCTs), thus denying old asthmatic individuals 
access to experimental observations and inter-
ventional studies. Our group has recently shown 
that asthmatics enrolled in RCTs are not fully rep-
resentative of real-life patients [6], and this is par-
ticularly true in elderly patients in whom the odds 
ratio to be excluded from RCTs increases to 18.6 
at the age of 75–84 years compared to the young-
est populations. The other factor that contributes 
to excluding elderly asthmatics from RCTs is the 
frequent occurrence of comorbidities, which are 
the norm in older individuals and tend to increase 
with ageing. The conclusion from the study by 
Battaglia et al. [6] is that almost half of elderly 
asthmatics are treated with drugs that have not 
been tested in such populations.
The frequent coexistence of comorbid condi-
tions in older patients, which are higher in num-
ber and different than those detected in younger 
asthmatics, may complicate the management of 
asthma. Comorbidities (and polypharmacy) can 
influence the metabolism and excretion of respi-
ratory drugs, and can negatively impact adherence 
to and persistence with chronic treatment. For the 
above reasons, the optimal control of the disease 
in older ages cannot be achieved without includ-
ing a multidimensional approach with a multidis-
ciplinary intervention. We propose to use the more 
comprehensive “geriatric asthma” instead of the 
generic and somewhat restrictive “asthma in the 
elderly”, which is only descriptive of the prevalence 
in a specific age group. A holistic approach is advo-
cated when physicians deal with elderly subjects 
who suffer from asthma and may be the key factor 
to attain optimal control of the disease in this age 
range.
Diagnosis of asthma in 
advanced age
One of the crucial issues related to asthma in the 
most advanced ages is the proper recognition of 
the disease. The question is whether the tradi-
tional diagnostic algorithm can be applied in older 
individuals. Are the tools employed and the criteria 
used suitable also for older populations or should 
they be modified (or used differently) based on 
age-related changes? In approaching the differen-
tial diagnosis of asthma in the elderly, physicians 
may be faced with several issues, including the 
objective (i.e. spirometric) evaluation of airway 
obstruction and modifications of clinical presen-
tation of asthma. It has been shown that <50% of 
patients with a new diagnosis of asthma receive 
objective pulmonary function testing, and this 
percentage decreases to 42%, 29% and 9.5% in 
patients aged 70–79, 80–89, and 90–99 years, 
respectively [7]. It is plausible to hypothesise that 
both overdiagnosis and underdiagnosis of asthma 
in the elderly would be lower if objective diag-
nostic testing were used widely. Obvious difficul-
ties exist in performing spirometry in the elderly, 
mainly because of the not trivial prevalence of 
cognitive impairments; several tests of cognition 
have been investigated as predictors of inability 
to perform spirometry in old ages [8, 9]. These 
include the Mini Mental State Examination, inabil-
ity to copy intersecting pentagons and clock draw-
ing tests, with the first two being more appropriate 
in predicting inability to perform spirometry in old 
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age [8]. All of them are easy to perform and require 
only a few minutes, which suggests that a rapid 
cognitive assessment should be part of the mul-
tidimensional management of geriatric asthma. It 
has been demonstrated that the vast majority of 
elderly subjects is capable of performing accept-
able and reproducible spirometries [10, 11] and 
carbon monoxide diffusion capacity tests [11], if 
the personnel are adequately trained. Moreover, 
specific “age-tailored” tests, such as the measure-
ment of the forced expiratory volume in the first 
6 s (FEV6), has been shown to be useful in those 
patients in whom the complete expiration and, 
thus, the achievement of a valid forced vital capac-
ity (FVC) can be difficult [12]. The use of FEV6 as 
substitute for FVC has the advantage of requiring 
an easier and faster manoeuvre, with less physical 
effort for patients.
Correct interpretation of spirometric curves in 
the elderly is probably the most difficult task for 
nontrained physicians. The physiological changes 
in the respiratory system due to the normal ageing 
process may confuse the picture. One of the most 
debated issues about spirometry in the elderly is 
the need for appropriate reference values in order 
to identify obstruction and restriction without 
misclassification [13]. As mentioned, physiological 
changes of the respiratory system with ageing may 
mimic the presence of airway obstruction. In this 
context, the so-called senile lung presents with fea-
tures of lung hyperinflation and the healthy elderly 
may appear to be emphysematous patients [14]. 
However, in the senile lung, the destruction of 
the lung parenchyma (i.e. emphysema) is absent, 
whereas a homogeneous enlargement of the alve-
olar airspaces is documented. The senile lung can 
be easily distinguished from the emphysematous 
lung, by measuring the lung density by computed 
tomography [15]. In this context, the static elastic 
recoil pressure of the lung diminishes [16], caus-
ing reduction in flow rates and vital capacity. The 
increased compressibility of the airways with age 
becomes evident at low lung volumes, where the 
reduction in lung elastic recoil overcomes that 
of the airways, leading to airflow limitation and 
airway closure. In recent years, several research 
groups have published reference equations for 
spirometric parameters obtained from cohorts 
of elderly subjects [17–22]. In evaluating a spiro-
metric test in the elderly, physicians need to use 
software that allows the selection of the appropri-
ate set of reference values in order to prevent mis-
classifications; in particular, for borderline values, 
the main risk is of classifying the healthy elderly 
as mildly obstructed. To date, reference values 
covering all ages (from infancy to geriatric age in a 
unique dataset [17]) are available. The use of these 
equations, instead of separate equations for adults 
and the elderly, may prevent confusion in inter-
preting spirometry in older individuals [23].
Perhaps the most challenging task in interpreting 
airway obstruction in the elderly is the differentiation 
of asthma from COPD. The above-described struc-
tural changes of the lung lead to a condition of the 
airways that is no longer susceptible to the effects 
of treatment, accounting for the loss of revers-
ibility and the persistence of airway obstruction. 
The possibility of development of fixed airflow 
limitation in elderly asthmatics may contribute to 
generating confusion, as the scholastic distinc-
tion between the two chronic respiratory diseases 
based on the degree of response to a rapidly acting 
bronchodilator agent loses its strength. However, 
it has been demonstrated that elderly subjects 
with a history of asthma have  different pathology 
compared to subjects with a history of COPD, even 
in the presence of fixed airflow limitation [24]. 
Moreover, the presence of physical disability may 
lead to misdiagnosis of COPD in elderly asthmat-
ics [25]. Even smoking history is not a clear-cut 
condition to distinguish asthmatics from indi-
viduals with COPD: about one out of three adult 
asthmatics is a current smoker [26]. What are 
the clinical implications of this assumption? An 
obstructed elderly subject with a long history of 
asthma should be treated as an asthmatic (not as 
COPD), regardless of the presence of reversibility 
of bronchial obstruction.
What are then the additional tools to help to 
recognise asthma or to exclude other respira-
tory conditions? Emphysema is not a feature of 
long-standing asthma in the elderly, and the dif-
fusing capacity of the lung for carbon monoxide 
(DLCO) should be normal and therefore used to 
differentiate asthma from COPD [27]. Neverthe-
less, Gelb et al. [28] demonstrated the presence of 
unsuspected mild emphysema in adult nonsmok-
ing patients with asthma and airway obstruction. 
However, these observations are limited to two 
cases that were autopsied, thus limiting the appli-
cability in clinical practice. The Global Allergy and 
Asthma European Network (GA2LEN) survey [29] 
demonstrated that subjects aged >45 years were 
less likely to have at least one positive skin prick 
tests for each tested allergen (including grass, cat, 
dog, house dust mite, birch, Artemisia, olive and 
Alternaria) except for Parietaria and Blattella, com-
pared with subjects aged <45 years. The GA2LEN 
findings are in line with previous literature that 
showed a decline of allergen sensitisations with 
age [30]. Ageing is associated with modifications 
of the immune system, defined as immunosenes-
cence. This could contribute to a reduced preva-
lence of allergic diseases in elderly populations. 
In this regard, atopy has rarely been considered in 
the clinical assessment of the geriatric respiratory 
patient. Although information on allergies in the 
elderly are scanty, positive skin tests have been 
reported in a variable percentage of older adults 
ranging from 8% to 12%, or even higher [31]. 
Indeed, elderly individuals with asthma have 
more evidence of atopy than age-matched con-
trols without asthma [32]. In this context, some 
authors have proposed the evaluation of atopy as 
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a useful tool in the differential diagnosis between 
asthma and COPD in the elderly [33]. However, 
this matter has not been investigated thoroughly 
and current guidelines rightly do not include the 
assessment of the allergic component to distin-
guish asthma from COPD. However, it is com-
monly accepted that the airways of atopic subjects 
are inflamed. The question is whether the state of 
atopy-related airway inflammation is responsible 
for the development of the obstructive phenotype 
that persists even when the inflammation dimin-
ishes as a consequence of reduction in the atopic 
state. From a clinical perspective, allergic reactions 
in older adults can have the same or even worse 
manifestations than in young people. A significant 
association between indoor allergen sensitisation 
and the occurrence of asthmatic symptoms was 
found in the Normative Aging Study, which was 
conducted in older men [34]. Taken together, 
these observations warrant the evaluation of atopy 
in the elderly [30]. It must be recognised that the 
two disorders may coexist in the same individual, 
leading to the “asthma–COPD overlap syndrome”. 
This nosological entity becomes relevant in 
patients aged >70 years in whom the proportion 
of patients with airflow obstruction who have an 
overlap syndrome may be as high as 60% [35, 36].
Exhaled nitric oxide fraction (FeNO) has been 
proposed as a marker of airway eosinophilic 
inflammation; therefore, it is plausible that it 
could play a role in the diagnosis of asthma in 
elderly patients. Unfortunately, data that have 
specifically addressed this issue are limited and 
mostly influenced by the use of inhaled corticoste-
roids (ICS) [37]. Of note, in healthy subjects, FeNO 
levels appear to show a triphasic shape with an 
ascendant loop during adolescence, a plateau in 
adults and a linear increase in the elderly until age 
80 years [38]. Modern technology, not yet avail-
able in clinical practice, may open new frontiers 
in the diagnosis of asthma, even in cases of fixed 
airway obstruction. A promising procedure is the 
analysis of exhaled air molecular profiles by elec-
tronic nose. This innovative methodology can ade-
quately distinguish patients with fixed asthma and 
COPD and, intriguingly, it can do it regardless of 
current smoking and the use of inhaled drugs [39].
From a clinical point of view, it has been 
reported that clinical features of asthma do not 
differ between very old (>80 years) and younger 
patients [40]. However, the possibility exists that 
subjects aged 80 years and over represent a high 
selected group of “survivors”, which limits the 
extrapolation to all elderly patients. Indeed, other 
studies in asthmatics aged >65 years showed 
a more severe and uncontrolled asthma than in 
younger asthmatics. Table 1 describes the main 
pitfalls in the diagnostic approach to elderly 
patients with symptoms suggestive of asthma.
Pharmacological challenges 
in the treatment of geriatric 
asthma
Asthma in the geriatric population appears to 
be widely undertreated [41]. The treatment of 
asthma in geriatric age follows international 
guidelines [27], although most recommendations 
are extrapolated from findings in younger sub-
jects. As already discussed, older age has always 
represented an exclusion criterion for eligibility 
in clinical trials and current asthma medications 
have never been tested in elderly asthmatics. The 
care of older asthmatics should address different 
domains such as comorbidities and polypharma-
cotherapy. The latter has been demonstrated to 
be one of the strongest predictors and the most 
important risk factor for adverse drug reactions 
in the elderly [42]. Therefore, particular attention 
should be given to concomitant nonrespiratory 
medications, since they can interfere with respi-
ratory drugs or with the disease [43]. For instance, 
β-blockers, frequently prescribed in elderly sub-
jects who suffer from cardiovascular diseases 
or administered as eye drops for glaucoma, can 
 facilitate bronchoconstriction.
Ageing is associated with pharmacokinetic 
changes that are primarily due to the decline in 
the function of the liver and the kidneys. As a con-
sequence, absorption, distribution,  metabolism 
and excretion of anti-asthmatic medications 
can be affected to a variable extent. Absorption 
Table 1 Common pitfalls in diagnosing asthma in the elderly
Pitfall Is it useful in 
diagnosing asthma?
Comments Ref.
Absence of reversibility No Elderly asthmatics may develop fixed airflow limitation [24]
Impaired DLCO Yes DLCO should be normal in asthmatics [27]
Smoking No Unfortunately, asthmatic patients do not avoid smoking [26]
Disability No Presence of disability is not confined to COPD [25]
Absence of allergy No Elderly asthmatics often are nonatopic [30, 31]
Presence of allergy Possibly If associated with a long disease duration [25, 30]
Long disease duration Possibly Asthma starting in young age does persist [24]
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is the pharmacokinetic parameter least affected 
by ageing; however, the prevalence of defects 
in the absorption may delay the time of onset 
of action of some drugs [44]. The prevalence of 
chronic renal failure increases with age and has 
been demonstrated to have negative prognostic 
implications [45]. In this case, the risk of adverse 
drug reactions is augmented by the fact that renal 
failure is often unrecognised due to normal lev-
els of serum creatinine. Reduced hepatic clear-
ance of drugs increases the potential for drug 
interactions. From a clinical perspective, to limit 
the risk of drug interaction, the dosage should be 
reduced for hepatically or renally cleared drugs. In 
addition, appropriate monitoring plans should be 
in place and the drug interaction should be doc-
umented in medical records. Whenever possible, 
clinicians should be encouraged to consider sub-
stitution of the suspected drug with another drug 
of similar efficacy but lower potential for interac-
tions. Importantly, caregivers should be informed 
about the potential risks and should be asked to 
be vigilant [46]. In elderly subjects, the lack of 
coordination between activation of the device 
and inhalation of the active drug may increase the 
oral deposition and decrease the lung deposition, 
thus reducing the efficacy and increasing local and 
 systemic side-effects.
ICS are the cornerstone of the pharmacological 
management of patients with persistent asthma 
[27] at all ages. However, particularly in the geri-
atric population, the long-term and high-dose 
use of ICS may be associated with increased risk 
of adverse events. Factors such as the patient’s 
inhalation technique and peak inspiratory flow, 
which are variably impaired in elderly patients, 
can increase the occurrence of side-effects. These 
include skin bruising, osteoporosis and bone frac-
tures, cataracts, glaucoma, oral candidiasis, diabe-
tes, and pneumonia.
The pharmacokinetic and pharmacodynamic 
features of the ICS are influenced by protein bind-
ing and bioactivation by first-pass metabolism 
in the liver. In clinical practice, clinicians should 
be aware that the hepatic metabolism can be 
the cause of drug interactions. For example, the 
concomitant use of itraconazole, clarithromycin 
or calcium-channel blockers may increase the 
bioavailability of ICS and the risk of toxicity [47]. 
In addition, the increased systemic bioavailability 
can be responsible for the potential suppression 
of the hypothalamic–pituitary–adrenal axis. When 
the risk of interaction of ICS with other drugs is 
suspected, the use of the minimum efficacy dose 
of ICS and a closer clinical follow-up are rec-
ommended. If prolonged co-administration of 
enzymatic inhibitors is required, the alternative 
approach is the choice of a corticosteroid that is 
metabolised through a process of hydrolysis (i.e. 
beclomethasone).
Bronchodilators are also affected by age-
ing-related changes of their pharmacokinetic and 
pharmacodynamic properties [48]. This has been 
demonstrated for β2-agonists, anticholinergics 
and theophylline [49]. β2-adrenergic agonists, 
either short-acting β2-agonists or long-acting 
β2-agonists (LABAs), bind the β-adrenoceptor, 
whose response is different in elderly asthmat-
ics due to increased sympathetic system activ-
ity, reduction in adenyl cyclase responses, and 
reduction in β2-adrenergic receptor number and 
affinity with ageing [50]. β2-agonists induce a 
net influx of intravascular potassium into cells, 
with subsequent electrolyte disorder. Thus, in 
older asthmatics, hypokalaemia, QT prolonga-
tion, tachycardia and tremor, which are medi-
ated by the systemic drug absorption and are 
dose dependent, are the most serious adverse 
effects. Of course, the coexistence of cardio-
vascular disorders increases the frequency and 
severity of side-effects [51]. Anticholinergic drugs 
might represent a valid alternative to β2-agonists; 
however, their use in the elderly should take into 
consideration the potential risk of side-effects. 
The anticholinergic response is different in older 
asthmatics due to a decrease in parasympathetic 
activity and reduction in receptor numbers or 
post-receptor coupling with age [49]. The most 
frequent side-effects are dry mouth and unpleas-
ant taste, contributing in older people to reduced 
ability to speak, mucosal damage and respiratory 
infection due to the reduction of antimicrobial 
activity of saliva [52]. Reduction of gastrointesti-
nal motility, urinary hesitancy and exacerbations 
of glaucoma can be also observed in older indi-
viduals. In addition, due to the reduced metab-
olism and drug elimination in older patients, 
chronic use of anticholinergic drugs may induce 
mild cognitive impairment. Finally, in three out of 
1000 patients a paradoxical bronchoconstriction 
may occur [49]. Theophylline treatment is limited 
by its narrow therapeutic range, the risk of inter-
action with several drugs and variable pharmaco-
kinetics among patients. Since it is administered 
in tablets, theophylline may overcome the com-
mon issues related to the proper use of inhalers; 
however, this drug carries the highest frequency 
of side-effects in the elderly, in whom its clear-
ance is reduced and increased blood levels are 
observed. The most frequent side-effects are 
gastrointestinal symptoms and arrhythmias. Sev-
eral studies have demonstrated that theophylline 
metabolism and clearance decrease in the elderly 
[53–55]. The clearance of theophylline is reduced 
by 22–35% in elderly people and it is further 
decreased by concomitant diseases, particularly 
liver and heart diseases [56]. The phosphodi-
esterase 4 inhibitor roflumilast is available for 
COPD treatment and its use in asthma can be an 
interesting add-on therapeutic option in severe 
asthma with frequent exacerbations. Its use in 
clinical practice is, however, limited by the risk of 
side-effects, which are dose-dependent, making 
the range of efficacy/tolerability very narrow.
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Leukotriene receptor antagonists (LTRA), such 
as montelukast, are an interesting alternative 
treatment to ICS and LABA in the elderly. On one 
hand, they can contribute to improving patients’ 
adherence in those with problems in manag-
ing inhaler devices; on the other hand, they may 
increase the safety of asthma therapy by avoiding 
ICS and LABA side-effects, which are more fre-
quent in the elderly. As an example, LTRA can be 
proposed as an alternative to β2-agonists when 
hearth failure and/or ischaemic heart disease are 
present, becoming the first-line drugs for elderly 
asthmatics with a recent history of cardiovascular 
events.
An exciting field in the treatment of asthma 
is the possibility to treat elderly patients with 
severe asthma with monoclonal antibodies (i.e. 
omalizumab). Previously published data have 
confirmed that omalizumab is as effective in 
elderly asthmatics as it is in younger patients: 
in different studies, anti-IgE treatment was 
shown to reduce exacerbations and symptoms in 
patients aged 50 years and over [57–59]. In addi-
tion to the anti-IgE monoclonal antibody, novel 
therapies are currently being explored in exper-
imental studies for severe asthma, although to 
our knowledge, no specific treatment is dedi-
cated to older asthmatic patients. Prospective tri-
als are needed to understand the effectiveness of 
monoclonal antibodies in the treatment of severe 
asthma in the geriatric ages.
Comorbid conditions
The geriatric patient is (almost by definition) char-
acterised by the concomitant occurrence of mul-
tiple diseases, the number of which increases with 
ageing. Elderly asthmatics are not an exception. 
The number of comorbidities in older asthmat-
ics is higher than that encountered in younger 
subjects, as recently demonstrated [60], and the 
pattern is different from that observed in younger 
asthmatics. Soriano et al. [61] demonstrated that 
in elderly asthmatics, the spectrum of comorbidi-
ties in primary care resembles that of COPD, with 
angina (3.5%), cataract (3.0%) and osteoporosis 
(2.7%) being the most prevalent conditions. These 
observations have obvious clinical implications. In 
this perspective, the higher prevalence of comor-
bidities observed in elderly asthmatics does not 
seem to be associated with worsened asthma 
control. It is rather the excessive number of med-
ications that indirectly affects asthma control in 
elderly asthmatics, by worsening the adherence 
to antiasthmatic treatment and increasing the 
risk of drug-to-drug interactions, with consequent 
impaired efficacy and safety.
What are the most common comorbid condi-
tions experienced in elderly patients in real life? 
Mood changes, such as depression and anxi-
ety, are very common in the geriatric patient, 
because asthma symptoms influence  emotional 
well-being dramatically. The impact of depres-
sion on asthma in the elderly has been widely 
demonstrated; depression is associated with 
poor asthma outcomes, including a higher rate of 
exacerbations [62] and higher mortality rates [4]. 
It is logical to assume that the negative effect of 
depression on the natural history of asthma is 
through the worsening of the level of adherence 
to treatment, which is common in depressed 
individuals. Elderly patients with asthma are also 
frequently affected by cognitive impairments. 
This comorbid condition can be underdiagnosed 
in clinical practice and have detrimental con-
sequences for the control of asthma. Indeed, 
subjects suffering from even mild cognitive 
impairment may experience impaired percep-
tion of asthma symptoms and poor medication 
adherence [63]. An increased risk of new onset 
atrial fibrillation was recently demonstrated in 
asthmatics [64]. This observation deserves atten-
tion in clinical practice based on the chronic use 
of bronchodilators that could worsen the cardiac 
disease. Table 2 provides an attempt to distin-
guish the comorbidities in geriatric asthma in 
order to improve outcome in real life.
Inhalation technique
The pharmacological management of asthma is 
mainly based on inhalation therapy. In the elderly, 
the patients’ ability to handle the inhalers may 
then play an important role. Inhaler technique is 
strongly influenced by the cognitive impairments, 
both those clinically evident (i.e. dementia) and 
those subclinical, which are more difficult to 
detect and more prevalent in the geriatric popula-
tion. Elderly asthmatics have been demonstrated, 
however, to improve their inhaler technique if 
practical demonstration and coaching are pro-
vided [65]. This implies that older asthmatics 
should receive appropriate instructions and the 
inhaler technique should be constantly assessed. 
Moreover, physical impairments, including arthri-
tis, visual problems or inability to generate an ade-
quate inspiration flow for a specific device, should 
be taken into account for the proper choice of 
device.
Unanswered questions
In the evaluation of the functional determinants 
of asthma in the elderly, the short-term response 
to a course of oral corticosteroids or the long-
term response to ICS could be a surrogate of the 
acute response to short-acting bronchodilators. 
This is an interesting area of research in the geri-
atric population.
A myth in the functional assessment of asthma 
in the elderly is the assumption that obtaining 
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optimal spirometries of good quality in older ages 
is an impossible mission. No doubt, spirometry is 
an effort-dependent manoeuver, and the collabo-
ration of the patient together with the interaction 
between the patient and the operator are manda-
tory. However, elderly subjects may perform good 
quality spirometry to the same extent as younger 
patients. Bellia et al. [10] demonstrated that as 
much as 90% acceptable and reproducible spi-
rometries were obtained in elderly subjects with 
or without chronic respiratory diseases.
An interesting area of research is to explore 
whether multiple comorbid conditions share a 
common systemic pathway; for instance, the 
metabolic syndrome could be pathogenetically 
linked to asthma through the pro-inflammatory 
low-density lipoproteins (LDL), as suggested by 
Scichilone et al. [66] and by Barochia et al. [67]. 
Small LDL could lead to the amplification of the 
inflammatory cascade in asthma: larger studies 
specifically designed to confirm the association 
between asthma and dyslipidaemia in the geriatric 
asthma are strongly needed.
The use of complementary/alternative med-
icines (CAMs) is a widespread phenomenon, 
common at any age. In asthma, homeopathy, 
acupuncture, herbal medicines and yoga are the 
most utilised techniques [68]. Asthmatics ask for 
CAMs because of the common belief that CAMs 
are more natural and safe, and this is particularly 
Table 2 Comorbidities in geriatric asthma
 Comorbidities Advice
Related to shared risk factors Rhinitis
Gastro-oesophageal reflux
Treat independently to improve 
asthma outcomes
Related to ageing Depression
Cognitive impairment
Assess to avoid drug interaction or 
treatment failure
Related to asthma treatment Cataracts
Osteoporosis
Arrhythmias
Diabetes
Monitor during asthma treatment 
to reduce drug dosages
Self-evaluation questions
1. Which of the following is true for a 75-year-old patient with fixed airflow limitation and a history of asthma from adolescence?
a. They should be treated as a “COPD” patient, i.e. using inhaled bronchodilators as first-line therapy
b. They should be treated as an “asthmatic” patient, i.e. using inhaled steroids as first-line therapy along with bronchodilators
c. Skin-prick tests are mandatory before initiating any treatment
d. Radiography is necessary to exclude COPD
2. Which of the following algorithms should be used in diagnosing asthma in the elderly?
a. Clinical history; spirometry; bronchodilator test; DLCO; skin prick test
b. Skin prick test; chest radiography; spirometry; DLCO; bronchodilator test
c. High-resolution computed tomography of the chest; spirometry; bronchodilator test
d. Clinical history; skin-prick test; chest X-ray
3. A 70-year-old man has a poor controlled asthma despite the use of controller medications. Could the physicians evaluate the 
patient’s eligibility to anti-IgE treatment?
a. No, because clinical trials have not investigated the effectiveness of monoclonal antibodies in the treatment of severe asthma 
in the geriatric population
b. No, due the modifications of the immune system (immunosenescence) associated with ageing
c. Yes, published data have confirmed that omalizumab in elderly asthmatics is effective as in younger asthmatics
d. No, its use in clinical practice is strongly limited by the risk of side-effects.
4. A 72-year-old female who has never smoked is diagnosed with moderate asthma. She suffers from depression, diabetes, arterial 
hypertension and diffuse arthritis of the hands. What is the most appropriate pharmacological approach?
a. She should not undergo any inhaled treatment because of difficulties in handling the device. Adrenaline should be prescribed 
for acute attacks.
b. Depression will certainly affect adherence to treatment. Oral treatment (antileukotrienes, theophylline and oral 
corticosteroids) should be preferred on regular basis.
c. Based on the arthritis of her hand, the most suitable inhaler device should be selected, and the patient should be properly 
informed and coached.
d. A metered-dose inhaler is to be preferred to dry-powder inhaler because of ease of use.
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true in elderly patients who are administered 
a large amount of medications and have fear of 
drug interactions. However, the vast majority of 
the clinical trials published on CAMs do not seem 
to meet the acceptable level of quality [69], often 
making the results difficult to interpret. Obviously, 
some of the CAM techniques are self-applied (yoga 
and relaxation techniques) and, therefore, blinded 
randomised trials are impossible.
Conclusions
The above-described features of geriatric asthma 
call for a different approach to this pathological 
condition. Based on what has been discussed, 
the management of asthma in the elderly should 
switch from a disease-oriented scheme to a dys-
function-oriented behaviour. In addition to a 
comprehensive lung function assessment, which 
should incorporate measurements of static and 
dynamic lung volumes together with DLCO, a 
multidimensional approach is recommended to 
establish the complexity of the disease. A com-
prehensive algorithm for the management of geri-
atric asthma is proposed in figure 1. We  suggest 
that the term “geriatric” asthma should be pre-
ferred to “senile” asthma, which confines the dis-
ease to the age-related structural and functional 
changes in the lung, or the more generic “asthma 
in the elderly”, which is only descriptive of the 
prevalence in old age groups. Geriatric asthma 
is no longer an enigma for general practitioners, 
nor is it an “orphan” disease for specialists; on 
the contrary, accumulating evidence confirms 
that the time has come to implement its dedi-
cated (multidimensional) management in clinical 
practice.
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